Nanosphere Health Sciences Inc
2CG
Company Profile
Business description
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.
Contact
605 Robson Street
c/o Suite 430
VancouverBCV6B 5J3
CANT: +1 604 351-3351
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
stocks
Fair value upgrade for ASX listed fast food chain
Earnings beat lifts forecasts but long term growth questions remain.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,374.90 | 50.40 | 0.54% |
| CAC 40 | 8,491.36 | 38.35 | 0.45% |
| DAX 40 | 26,320.75 | 214.15 | 0.82% |
| Dow JONES (US) | 53,417.16 | 140.15 | 0.26% |
| FTSE 100 | 10,867.80 | 13.48 | 0.12% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 25,980.19 | 200.27 | -0.76% |
| Nikkei 225 | 65,856.43 | 328.34 | 0.50% |
| NZX 50 Index | 13,992.72 | 110.84 | 0.80% |
| S&P 500 | 7,652.86 | 21.51 | -0.28% |
| S&P/ASX 200 | 9,164.60 | 54.30 | 0.60% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |